AURA Janet Jill Hopkins sells $111K worth of shares
Nov 19, 2024, 5:33 AM
-6.87%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
Janet Jill Hopkins sold 11,822 shares of AURA on 18 November at $9.36 per share, worth a total of $111K. They now own 151,693 AURA shares, or a 7% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.